- Home
- URGN vs QNST Comparison
URGN vs QNST Comparison
Compare URGN & QNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- QNST
- Stock Information
- Founded
- URGN 2004
- QNST 1999
- Country
- URGN United States
- QNST United States
- Employees
- URGN N/A
- QNST N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- QNST Business Services
- Sector
- URGN Health Care
- QNST Consumer Discretionary
- Exchange
- URGN Nasdaq
- QNST Nasdaq
- Market Cap
- URGN 1.1B
- QNST 923.2M
- IPO Year
- URGN 2017
- QNST 2010
- Fundamental
- Price
- URGN $27.39
- QNST $14.10
- Analyst Decision
- URGN Strong Buy
- QNST Buy
- Analyst Count
- URGN 8
- QNST 5
- Target Price
- URGN $28.50
- QNST $26.40
- AVG Volume (30 Days)
- URGN 1.4M
- QNST 585.7K
- Earning Date
- URGN 11-06-2025
- QNST 11-06-2025
- Dividend Yield
- URGN N/A
- QNST N/A
- EPS Growth
- URGN N/A
- QNST N/A
- EPS
- URGN N/A
- QNST 0.18
- Revenue
- URGN $96,516,000.00
- QNST $1,100,345,000.00
- Revenue This Year
- URGN $35.07
- QNST $11.18
- Revenue Next Year
- URGN $117.83
- QNST $9.54
- P/E Ratio
- URGN N/A
- QNST $79.30
- Revenue Growth
- URGN 8.00
- QNST 43.12
- 52 Week Low
- URGN $3.42
- QNST $12.98
- 52 Week High
- URGN $27.98
- QNST $25.50
- Technical
- Relative Strength Index (RSI)
- URGN 74.68
- QNST 49.09
- Support Level
- URGN $24.69
- QNST $12.98
- Resistance Level
- URGN $26.28
- QNST $13.66
- Average True Range (ATR)
- URGN 1.87
- QNST 0.63
- MACD
- URGN 0.32
- QNST 0.01
- Stochastic Oscillator
- URGN 95.93
- QNST 38.75
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia.